| Literature DB >> 31453437 |
Astrid Rasmussen1, Donald U Stone2, C Erick Kaufman3, Kimberly S Hefner4, Nicole R Fram5, Rhea L Siatkowski6, Andrew J W Huang7, James Chodosh8, Pablo T Rasmussen9, Dustin A Fife10, Nathan Pezant10, Kiely Grundahl10, Lida Radfar3, David M Lewis3, Michael H Weisman11, Swamy Venuturupalli11, Daniel J Wallace11, Nelson L Rhodus12, Michael T Brennan13, Courtney G Montgomery10, Christopher J Lessard14, R Hal Scofield15, Kathy L Sivils14.
Abstract
OBJECTIVE: The objective of this study was to assess the performance and reproducibility of the two currently used ocular surface staining scores in the assessment of keratoconjunctivitis sicca in Sjögren syndrome (SS) research classification.Entities:
Year: 2019 PMID: 31453437 PMCID: PMC6710016 DOI: 10.1002/acr2.1033
Source DB: PubMed Journal: ACR Open Rheumatol ISSN: 2578-5745
Figure 1Diagram of scoring of the van Bijsterveld score (vBS) and the Ocular Staining Score (OSS). A, Semiquantitative method for determining the vBS as described originally by van Bijsterveld 8 and incorporated into the American European Consensus Group (AECG) classification criteria 4, 34. However, for this study and to diminish interrater subjectivity, a dot‐counting method based on the OSS was used to determine the vBS 14. B, The OSS with the three additional corneal staining points. The original cutoff level of the OSS was three or more 12; however, a cutoff level of five or more has been adopted for the American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) classification criteria 5.
Effect and predictive value of the Ocular Staining Score additional corneal points on classification for primary SSa
| SS (n = 445), n (%) | Non‐SS Sicca (n = 549), n (%) | PPV (95% CI) | NPV (95% CI) | Odds Ratio (95% CI) |
| |
|---|---|---|---|---|---|---|
| Additional points (positive) | 201 (45) | 107 (20) | 0.66 (0.61‐0.71) | 0.65 (0.61‐0.69) | 3.66 (2.76‐4.85) | 1.65 × 10e‐20 |
| Confluent staining (positive) | 183 (41) | 83 (15) | 0.69 (0.63–0.74) | 0.64 (0.60‐0.67) | 3.92 (2.9‐5.29) | 2.44 × 10e‐20 |
| Pupillary staining (positive) | 138 (31) | 59 (11) | 0.70 (0.63‐0.76) | 0.61 (0.58‐0.65) | 3.37 (2.66‐5.23) | 1.25 × 10e‐15 |
| Filaments (positive) | 35 (8) | 16 (3) | 0.69 (0.54‐0.80) | 0.57 (0.53‐0.60) | 2.84 (1.55‐5.21) | 0.0005 |
Abbreviation: AECG, American European Consensus Group; CI, confidence interval; NPV, negative predictive value; PPV, positive predictive value; SS, Sjögren syndrome.
SS classification is based on AECG criteria. We excluded all participants with secondary SS or overlap syndromes or those with incomplete ocular assessments 4.
Participants with non‐SS sicca are participants who have self‐described sicca symptoms and meet at least one AECG criterion but do not meet enough criteria to be classified as having SS.
Association of the Ocular Staining Score additional corneal points with classification criteria for SSa
| Confluent Staining | Pupillary Staining | Filaments | Three CSPs | Six CSPs | |
|---|---|---|---|---|---|
| OR (95% CI), | OR (95% CI), | OR (95% CI), | OR (95% CI), | OR (95% CI), | |
| Anti‐Ro/SSA (positive) | 3.11 (2.32‐4.18), 6.34 × 10e‐15 | 2.82 (2.05‐3.89), 5.12 × 10e‐11 | 2.53 (1.44‐4.45), 5.16 × 10e‐04 | 3.24 (1.5‐6.64), 0.0038 | 1.63 (0.63‐3.84), 0.363 |
| Anti‐La/SSB (positive) | 2.54 (1.83‐3.52), 6.87 × 10e‐09 | 2.67 (1.88‐3.79), 9.26 × 10e‐09 | 3.07 (1.72‐5.49), 4.05 × 10e‐05 | 3.23 (1.42‐6.95), 0.0045 | 3.13 (1.29‐8.2), 0.018 |
| Biopsy (positive) | 2.73 (2.01‐3.7), 2.53 × 10e‐11 | 2.72 (1.93‐3.81), 1.87 × 10e‐09 | 1.91 (0.99‐3.68), 0.029 | 2.37 (1.05‐5.46), 0.038 | 1.09 (0.41‐2.8), 1.0 |
| Schirmer's test (positive) | 2.53 (1.9‐3.37), 6.54 × 10e‐11 | 3.33 (2.42‐4.58), 1.20 × 10e‐14 | 2.09 (1.08‐4.05), 0.015 | 3.29 (1.54‐6.89), 0.003 | 3.66 (1.24‐10.42), 0.032 |
| WUSF (positive) | 2.42 (1.79‐3.25), 1.99 × 10e‐09 | 2.88 (2.04‐4.07), 3.26 × 10e‐10 | 4.93 (2.29‐10.6), 3.99 × 10e‐06 | 3.81 (1.57‐8.95), 0.003 | 8.49 (1.34‐91.1), 0.014 |
Abbreviation: CI, confidence interval; CSP, corneal staining point; OR, odds ratio; SS, Sjögren syndrome; WUSF, whole unstimulated salivary flow.
Based on analysis of 316 participants with extra points: n = 209 for SS and n = 107 for non‐SS sicca. Presence (positive) 21 for each criterion is based on Vitali et al 4.
Figure 2Receiver operator curves for the performance of ocular surface staining scores versus Sjögren syndrome classification criteria. The table beneath each graph shows the area under the curve (AUC) and the sensitivity and specificity of the score at the present and past cutoff values for each classification system. A, the van Bijsterveld score (vBS) versus the American European Consensus Group (AECG) classification criteria. B, The Ocular Staining Score (OSS) versus the AECG classification criteria. C, the vBS versus the American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) classification criteria. D, the OSS versus the ACR/EULAR classification criteria. CI, confidence interval.
Figure 3Interrater reproducibility of the ocular surface staining scores. The median, minimum, and maximum scores of all the evaluations performed by 11 raters (A‐K) are shown. Each rater evaluated a different set and number of subjects, as shown in A. The difference of the medians was analyzed using the Brown‐Forsythe and Welch analysis of variance tests, correcting for multiple comparisons using Games‐Howell statistical hypothesis testing. The overall P value presented for raters A through K reflects the difference across all medians; the asterisks above each bar reflect the comparison of the individual rater versus the median of the scores of all raters. A, The median van Bijsterveld scores (vBS) by rater. B, The median Ocular Staining Scores (OSS) by rater.
Intrasubject variability of the vBS and the OSS in 20 subjects evaluated at two time points with a median gap of 5.5 years
| Subject | Year of Evaluation | Time Gap, y | vBS (Call) | OSS (Call) | Classification Item Change | |||
|---|---|---|---|---|---|---|---|---|
| First | Second | First | Second | First | Second | |||
| Same rater for both evaluations | ||||||||
| 1 | 2010 | 2017 | 7 | 7 (+) | 5 (+) | 9 (+) | 7 (+) | No change |
| 2 | 2010 | 2017 | 7 | 2 (−) | 1 (−) | 4 (−) | 1 (−) | No change |
| 3 | 2012 | 2017 | 5 | 5 (+) | 5 (+) | 6 (+) | 7 (+) | No change |
| 4 | 2013 | 2017 | 4 | 3 (−) | 3 (−) | 4 (−) | 3 (−) | No change |
| 5 | 2013 | 2017 | 4 | 5 (+) | 6 (+) | 6 (+) | 7 (+) | No change |
| 6 | 2015 | 2017 | 2 | 0 (−) | 0 (−) | 0 (−) | 0 (−) | No change |
| 7 | 2015 | 2017 | 2 | 6 (+) | 7 (+) | 7 (+) | 7 (+) | No change |
| 8 | 2015 | 2017 | 2 | 4 (+) | 0 (−) | 5 (+) | 0 (−) | Pos to neg |
| 9 | 2015 | 2017 | 2 | 4 (+) | 2 (−) | 5 (+) | 2 (−) | Pos to neg |
| Different rater for each evaluation | ||||||||
| 1 | 2008 | 2017 | 9 | 3 (−) | 1 (−) | 4 (−) | 2 (−) | No change |
| 2 | 2008 | 2017 | 9 | 2 (−) | 3 (−) | 2 (−) | 6 (+) | Neg to pos |
| 3 | 2009 | 2017 | 8 | 0 (−) | 1 (−) | 0 (−) | 1 (−) | No change |
| 4 | 2009 | 2017 | 8 | 3 (−) | 7 (+) | 3 (−) | 9 (+) | Neg to pos |
| 5 | 2009 | 2017 | 8 | 5 (+) | 1 (‐) | 6 (+) | 2 (−) | Pos to neg |
| 6 | 2009 | 2017 | 8 | 5 (+) | 3 (−) | 5 (+) | 3 (−) | Pos to neg |
| 7 | 2010 | 2017 | 7 | 9 (+) | 9 (+) | 11 (+) | 10 (+) | No change |
| 8 | 2011 | 2017 | 6 | 9 (+) | 7 (+) | 9 (+) | 9 (+) | No change |
| 9 | 2011 | 2017 | 6 | 9 (+) | 7 (+) | 9 (+) | 9 (+) | No change |
| 10 | 2014 | 2017 | 3 | 9 (+) | 3 (−) | 11 (+) | 3 (−) | Pos to neg |
| 11 | 2015 | 2017 | 2 | 7 (+) | 3 (−) | 9 (+) | 3 (−) | Pos to neg |
Abbreviation: ACR/EULAR, American College of Rheumatology/European League Against Rheumatism; neg, negative ocular staining; OSS, Ocular Staining Score; pos, positive ocular staining; vBS, van Bijsterveld score.
The cutoff values for the vBS and the OSS are based on the ACR/EULAR classification criteria 5.
Subjects whose ocular criterion changed between the two time points.
Items went from a positive (abnormal) score to a negative (normal) one.